Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

487 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: the PROTECT II study.
O'Neill WW, Kleiman NS, Moses J, Henriques JP, Dixon S, Massaro J, Palacios I, Maini B, Mulukutla S, Dzavík V, Popma J, Douglas PS, Ohman M. O'Neill WW, et al. Among authors: kleiman ns. Circulation. 2012 Oct 2;126(14):1717-27. doi: 10.1161/CIRCULATIONAHA.112.098194. Epub 2012 Aug 30. Circulation. 2012. PMID: 22935569 Clinical Trial.
Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade.
Lincoff AM, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ. Lincoff AM, et al. Among authors: kleiman ns. Circulation. 1999 Apr 20;99(15):1951-8. doi: 10.1161/01.cir.99.15.1951. Circulation. 1999. PMID: 10208997 Clinical Trial.
Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus: results of the EPISTENT (Evaluation of platelet IIb/IIIa inhibitor for stenting trial) diabetic substudy.
Marso SP, Lincoff AM, Ellis SG, Bhatt DL, Tanguay JF, Kleiman NS, Hammoud T, Booth JE, Sapp SK, Topol EJ. Marso SP, et al. Among authors: kleiman ns. Circulation. 1999 Dec 21-28;100(25):2477-84. doi: 10.1161/01.cir.100.25.2477. Circulation. 1999. PMID: 10604884 Clinical Trial.
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation.
Dyke CK, Becker RC, Kleiman NS, Hochman JS, Bovill EG, Lincoff AM, Gerstenblith G, Dzavik V, Gardner LH, Hasselblad V, Zillman LA, Shimoto Y, Robertson TL, Kunitada S, Armstrong PW, Harrington RA. Dyke CK, et al. Among authors: kleiman ns. Circulation. 2002 May 21;105(20):2385-91. doi: 10.1161/01.cir.0000016351.12759.52. Circulation. 2002. PMID: 12021225 Clinical Trial.
Evaluation of a new heparin agent in percutaneous coronary intervention: results of the phase 2 evaluation of M118 IN pErcutaNeous Coronary intErvention (EMINENCE) Trial.
Rao SV, Melloni C, Myles-Dimauro S, Broderick S, Kosinski AS, Kleiman NS, Dzavík V, Tanguay JF, Chandna H, Gammon R, Rivera E, Alexander JH, Fier I, Roach J, Becker RC; EMINENCE Investigators. Rao SV, et al. Among authors: kleiman ns. Circulation. 2010 Apr 20;121(15):1713-21. doi: 10.1161/CIRCULATIONAHA.109.913277. Epub 2010 Apr 5. Circulation. 2010. PMID: 20368520 Clinical Trial.
In-hospital and 1-year outcomes with drug-eluting versus bare metal stents in saphenous vein graft intervention: a report from the EVENT registry.
Tolerico PH, Cohen DJ, Kleiman NS, Berger PB, Brilakis ES, Piana RN, Shammo S, Keyes MJ, Kennedy KF, Massaro JM, Saucedo JF; EVENT Investigators. Tolerico PH, et al. Among authors: kleiman ns. Catheter Cardiovasc Interv. 2012 Dec 1;80(7):1127-36. doi: 10.1002/ccd.24352. Epub 2012 May 4. Catheter Cardiovasc Interv. 2012. PMID: 22431166
Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year.
Stolker JM, Cohen DJ, Kennedy KF, Pencina MJ, Lindsey JB, Mauri L, Cutlip DE, Kleiman NS; Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) Investigators. Stolker JM, et al. Among authors: kleiman ns. Circ Cardiovasc Interv. 2012 Dec;5(6):772-82. doi: 10.1161/CIRCINTERVENTIONS.111.967802. Epub 2012 Oct 23. Circ Cardiovasc Interv. 2012. PMID: 23093553
Percutaneous coronary intervention vs. coronary artery bypass graft surgery for unprotected left main coronary artery disease in the drug-eluting stents era--an aggregate data meta-analysis of 11,148 patients.
Alam M, Huang HD, Shahzad SA, Kar B, Virani SS, Rogers PA, Paniagua D, Bozkurt B, Palacios I, Kleiman NS, Jneid H. Alam M, et al. Among authors: kleiman ns. Circ J. 2013;77(2):372-82. doi: 10.1253/circj.cj-12-0747. Epub 2012 Oct 31. Circ J. 2013. PMID: 23123552 Free article. Review.
487 results